SIGLEC14

Across TCGA pan-cancer cohorts, SIGLEC14 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIGLEC14 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SIGLEC14 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SIGLEC14 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, READ, and COAD are the cancer types where SIGLEC14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.174	0.781	<.001	17	view →
READ	DFS	Median	All	0.269	0.819	.009	15	view →
COAD	OS	Median	III,IV	0.140	0.691	.017	7	view →
LGG	DFS	Median	All	0.249	0.753	.013	6	view →
UCEC	DFS	Median	All	1.000	0.630	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIGLEC14–SKCM (OS)

Open the SKCM breakdown →